Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PFE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure of CFO (new) — CFO leaving for role in different industry, though company states departure unrelated to financial issues or disagreements.
Pfizer CFO Dave Denton departing Aug 15 for consumer goods role; Guegan named interim
Filed June 18, 2026 · Period ending June 18, 2026 · ~1 min read
Key Changes
-
high
CFO Dave Denton stepping down Aug 15, 2026 for consumer goods opportunity outside pharma; company states departure unrelated to financial results or disagreements on accounting/reporting policies.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
medium
Cecile Guegan, 21-year Pfizer veteran and current SVP Finance for Global Biopharmaceutical Business, named Interim CFO effective Aug 16 while comprehensive internal/external search underway.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
medium
CEO credits Denton with overseeing major acquisitions including Seagen, Biohaven, and Metsera, characterized as among most important recent transactions expected to benefit company long-term.
Exhibit 99.1 view on EDGAR →
Summary
Pfizer's CFO Dave Denton is leaving the company effective August 15, 2026, to pursue a professional opportunity in the consumer goods sector. While the company explicitly states his departure is unrelated to Pfizer's financial or operating results and involves no disagreements on financial, operational, accounting, or reporting matters, the loss of a CFO who oversaw major recent acquisitions including Seagen, Biohaven, and Metsera represents a leadership transition at the senior finance level. The timing and industry switch warrant attention from investors monitoring executive stability.
Cecile Guegan, a 21-year Pfizer veteran currently serving as SVP Finance for the Global Biopharmaceutical Business, will serve as Interim CFO starting August 16 while the company conducts a comprehensive search for a permanent successor. Guegan's deep institutional knowledge and experience leading the Seagen integration in 2024 provide continuity during the transition. Investors should monitor the permanent CFO search process and any strategic or operational shifts during the interim period.
Section-by-Section Diff
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
Dave Denton, Chief Financial Officer, will step down from his current role and leave the company on August 15 for a professional opportunity outside of the pharmaceutical industry in consumer goods, which he has accepted.
Pfizer's CFO Dave Denton is leaving the company effective August 15, 2026, to pursue a role in the consumer goods industry. The departure is voluntary and for a professional opportunity outside pharmaceuticals. The company is conducting both internal and external searches for a permanent replacement.
Added in current filing · view on EDGAR →
The company has named Cecile Guegan, currently Senior Vice President, Finance, Global Biopharmaceutical Business, as Interim Chief Financial Officer, effective August 16, while Pfizer conducts a comprehensive internal and external search.
Cecile Guegan, currently SVP of Finance for Pfizer's Global Biopharmaceutical Business, will serve as interim CFO starting August 16, 2026. She has over two decades of experience at Pfizer and led the Seagen integration in 2024. The appointment is temporary while the company searches for a permanent CFO.
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 16, 2026, Dave Denton notified Pfizer Inc. (the “Company”) that he will step down from his current position as Chief Financial Officer effective August 15, 2026 for a professional opportunity outside of the pharmaceutical industry in consumer goods, and that his departure is not related to the Company’s financial or operating results or to any disagreements with the Company regarding the Company’s financial, operational, accounting or reporting policies or practices.
Dave Denton is leaving his CFO role effective August 15, 2026 to pursue a professional opportunity in the consumer goods sector. The company explicitly states his departure is unrelated to Pfizer's financial or operating results and involves no disagreements on financial, operational, accounting, or reporting matters.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 21, 2026 · How we verify